- Home
- NUVL vs AXTA Comparison
NUVL vs AXTA Comparison
Compare NUVL & AXTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- AXTA
- Stock Information
- Founded
- NUVL 2017
- AXTA 1910
- Country
- NUVL United States
- AXTA United States
- Employees
- NUVL N/A
- AXTA N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- AXTA Paints/Coatings
- Sector
- NUVL Health Care
- AXTA Consumer Discretionary
- Exchange
- NUVL Nasdaq
- AXTA Nasdaq
- Market Cap
- NUVL 5.8B
- AXTA 6.7B
- IPO Year
- NUVL 2021
- AXTA 2014
- Fundamental
- Price
- NUVL $77.76
- AXTA $27.83
- Analyst Decision
- NUVL Strong Buy
- AXTA Buy
- Analyst Count
- NUVL 10
- AXTA 15
- Target Price
- NUVL $119.60
- AXTA $39.20
- AVG Volume (30 Days)
- NUVL 482.8K
- AXTA 3.1M
- Earning Date
- NUVL 08-11-2025
- AXTA 07-30-2025
- Dividend Yield
- NUVL N/A
- AXTA N/A
- EPS Growth
- NUVL N/A
- AXTA 51.22
- EPS
- NUVL N/A
- AXTA 2.04
- Revenue
- NUVL N/A
- AXTA $5,198,000,000.00
- Revenue This Year
- NUVL N/A
- AXTA $2.10
- Revenue Next Year
- NUVL N/A
- AXTA $3.30
- P/E Ratio
- NUVL N/A
- AXTA $13.63
- Revenue Growth
- NUVL N/A
- AXTA N/A
- 52 Week Low
- NUVL $55.54
- AXTA $27.58
- 52 Week High
- NUVL $113.51
- AXTA $41.66
- Technical
- Relative Strength Index (RSI)
- NUVL 43.20
- AXTA 28.99
- Support Level
- NUVL $77.41
- AXTA $28.02
- Resistance Level
- NUVL $83.50
- AXTA $29.62
- Average True Range (ATR)
- NUVL 3.08
- AXTA 0.63
- MACD
- NUVL -0.75
- AXTA -0.20
- Stochastic Oscillator
- NUVL 14.84
- AXTA 7.74
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About AXTA Axalta Coating Systems Ltd.
Axalta Coating Systems Ltd is a manufacturer, marketer and distributor of high-performance coatings systems. It operates in two segments, The Performance Coatings segment provides liquid and powder coatings solutions to a fragmented and local customer base. Its end markets include refinish and industrial. The Mobility Coatings segment relates to the provision of coating technologies to original equipment manufacturers of light and commercial vehicles. The company operates in the geographic areas of North America, EMEA countries, Asia-Pacific, and Latin America.